Abstract:The neonatal fragment crystallizable (Fc) receptor (FcRn) transports IgG across mucosal surfaces and the placenta and protects IgG from degradation. Inhibition of this receptor results in both lysosomal degradation and prevention of cross‐placental transport, with a subsequent reduction in circulating IgG levels. FcRn inhibition does not impact the production of IgG, nor alter the levels of other immunoglobulin isotypes. Clinical trial data have thus far demonstrated that the risk of serious adverse events, including serious infections, appears to be lower than that seen with other commonly used immunomodulatory/immunosuppressive therapies. As such, FcRn inhibition represents a potential therapy for IgG‐mediated hematologic conditions (e.g., immune thrombocytopenia, autoimmune hemolytic anemia, immune thrombotic thrombocytopenic purpura, acquired hemophilia, red blood cell/platelet alloimmunization). This review summarizes the current evidence and highlights potential reasons why FcRn inhibitors may be a potential treatment option for a variety of hematologic conditions. The neonatal fragment crystallizable (Fc) receptor (FcRn) transports IgG across mucosal surfaces and the placenta and protects IgG from degradation. Numerous clinical trials are investigating therapeutic FcRn inhibition for various immune‐mediated neuromuscular and rheumatologic conditions; however, FcRn inhibition also represents a potential therapy for IgG‐mediated hematologic conditions (e.g., immune thrombocytopenia, autoimmune hemolytic anemia, immune thrombotic thrombocytopenic purpura, acquired hemophilia, red blood cell/platelet alloimmunization). Current evidence derived from both in vitro and in vivo studies suggests that FcRn inhibitors effectively reduce total IgG levels without impacting its production or altering the levels of other immunoglobulin isotypes. Moreover, the risk of serious adverse events, including serious infections, appears to be lower than that seen with other commonly used immunomodulatory/immunosuppressive therapies, albeit in the setting of limited clinical trial data. Ultimately, additional clinical trials that include varied patient populations are required prior to incorporating these agents into standard treatment algorithms for most hematologic conditions. However, based on the pathophysiology of IgG‐mediated hematologic disorders and the mechanism of action of FcRn inhibitors, these agents may represent a future novel therapeutic strategy for patients with hematologic conditions caused by IgG antibodies.

The Neonatal Fc Receptor (FcRn): A Misnomer?

The therapeutic age of the neonatal Fc receptor

Regulation of immune responses by the neonatal fc receptor and its therapeutic implications

Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions

MHC Class I-Related Neonatal Fc Receptor for IgG is Functionally Expressed in Monocytes, Intestinal Macrophages, and Dendritic Cells

[Neonatal Fc receptor : role and implications in maternal fetal medicine]

Identification of Four Mouse FcRn Splice Variants and FcRn-Specific Vesicles

The role of immunoglobulin transport receptor, neonatal Fc receptor in mucosal infection and immunity and therapeutic intervention

Neonatal Fc Receptor Regulation of Lung Immunoglobulin and CD103+ Dendritic Cells Confers Transient Susceptibility to Tuberculosis

The neonatal Fc receptor is expressed by human retinal pigment epithelial cells and is downregulated by tumour necrosis factor-alpha

Truncation of the Murine Neonatal Fc Receptor Cytoplasmic Tail Does Not Alter IgG Metabolism or Transport in Vivo.

Identifying the immunoglobulin G transporter in equine tissues: A look at the neonatal Fc receptor

The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors

Aduance in Immunoglobulin Fc Receptor in Neonatal Animal

Fc gamma receptors: Their evolution, genomic architecture, genetic variation, and impact on human disease

Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin

Binding to the neonatal Fc receptor enhances the pathogenicity of anti-desmoglein-3 antibodies in keratinocytes

A Restricted Role for FcγR in the Regulation of Adaptive Immunity

The MHC Class II-Associated Invariant Chain Interacts with the Neonatal Fcγ Receptor and Modulates Its Trafficking to Endosomal/Lysosomal Compartments

Presence and possible impact of Fcγ receptors on resident kidney cells in health and disease

Defining the Immunological Phenotype of Fc Receptor-Like B (FCRLB) Deficient Mice: Confounding Role of the Inhibitory FcγRIIb.